1. Scrip
  2. >>Business

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

 
• By Mandy Jackson

Gilead reported an expected and continued sales decline in HCV – an area in which the company soon will be done with R&D, since unmet needs have been filled or will be soon by drug regimens from Gilead and its competitors. The company is hunting new assets, but taking a disciplined approach on price and quality.

Gilead Sciences Inc. is preparing to shift its research and development focus away from the hepatitis C virus (HCV) as sales of its HCV blockbusters continue to decline in the face of payer pressures and increasing competition, including the company’s own pan-genotypic, short-duration product that will be submitted soon for regulatory approvals.

President and CEO John Milligan said during Gilead’s third quarter earnings call that “there isn’t much left in terms of unmet medical need,” so the company has no new R&D programs planned in HCV and will focus its drug and business development activities on medicines to treat other liver diseases, fibrosis, cancer and inflammatory diseases. Diversification of the pipeline is welcome news for investors as Gilead’s $7

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.